Breaking News

Oxygen Biotherapeutics, Hospira Sign Oxycyte Supply Pact

Oxygen Biotherapeutics, Inc. has reached a development and commercial supply agreement with Hospira's One 2 One Global Pharmaceutical Services business unit to manufacture clinical-grade Oxycyte, a perfluorocarbon (PFC) therapeutic oxygen carrier.

Oxygen Biotherapeutics, Inc. has reached a development and commercial supply agreement with Hospira’s One 2 One Global Pharmaceutical Services business unit to manufacture clinical-grade Oxycyte, a perfluorocarbon (PFC) therapeutic oxygen carrier. Hospira will formulate, fill, finish and label Oxycyte to meet clinical GMP standards and it will be manufactured at the company’s Clayton, NC facility.

“This agreement connects us to a first-tier contract manufacturer and superbly reliable supplier who will provide us with all the Oxycyte we need to grow the company. As I’ve previously stated, our strategy is to license marketing rights for individual indications, yet always control the supply of our compound and be able to profit from sales of Oxycyte to licensees,” said Chris J. Stern, company chairman and chief executive officer.

Financial terms were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters